{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:52:49Z","timestamp":1788562369095,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The ataxia-telangiectasia mutated (ATM) protein coordinates the cellular response to therapeutic radiation, and ATM inhibitors can potentially enhance the efficacy of radiation in otherwise radiation-resistant tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The small molecule ATM kinase inhibitor WSD0628 was specifically designed for enhanced distribution across the blood-brain barrier to more effectively treat glioblastoma (GBM) and brain metastases in combination with radiation therapy (RT). GBM and brain metastasis patient-derived xenograft models were used to understand target inhibition, radiosensitization, inhibition of the DNA damage response, and in vivo efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Initial in vitro characterization of WSD0628 demonstrates a high level of selectivity across kinase families, limited aldehyde oxidase liability, and low risk of hERG interactions. Consistent with a central role for ATM in radiation response, WSD0628 blocked radiation-induced signaling and enhanced radiosensitivity in U251 glioma cells and brain tumor PDXs GBM120 and M12. In comparison to control or RT alone in orthotopic PDXs, the combination of WSD0628 with RT markedly prolonged median survival\u2014GBM12 (19, 55, and 408 days, respectively); GBM43 (26, 44, and 143 days, respectively); GBM120 (51, 89, and 231 days, respectively); M12 (17, 39, and 190 days, respectively). Pharmacokinetic and pharmacodynamic testing after treatment in orthotopic GBM43 tumors showed inhibitory levels of WSD0628 and a reduction of \u03b3H2AX foci in the combination-treated tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Collectively, these results suggest a promising role for WSD0628 in combination with RT in brain tumors and provide the rationale for an ongoing Phase 0\/1A clinical trial testing this combination in recurrent GBM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noaf102","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T01:51:31Z","timestamp":1744681891000},"page":"2313-2325","source":"Crossref","is-referenced-by-count":9,"title":["The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts"],"prefix":"10.1093","volume":"27","author":[{"given":"Zhiyi","family":"Xue","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Cheeloo College of Medicine, Qilu Hospital, Shandong University , Jinan ,","place":["China"]},{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C","family":"Mladek","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Rathi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael A","family":"Vaubel","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lateef A","family":"Odukoya","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darwin A","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Liu","sequence":"additional","affiliation":[{"name":"Wayshine Biopharm Inc , Corona, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina K","family":"Bakken","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett L","family":"Carlson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren L","family":"Ott","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M","family":"Burgenske","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Dragojevic","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3756-4227","authenticated-orcid":false,"given":"Paul A","family":"Decker","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L","family":"Kosel","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G","family":"Breen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette E","family":"Eckel-Passow","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F","family":"Elmquist","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Wayshine Biopharm Inc , Corona, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7489-4885","authenticated-orcid":false,"given":"Jann N","family":"Sarkaria","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"8","key":"2025101514162587400_CIT0001","first-page":"CD013047","article-title":"Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma","volume":"8","author":"Lawrie","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2025101514162587400_CIT0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.semradonc.2014.06.006","article-title":"Recurrent malignant gliomas","volume":"24","author":"Kirkpatrick","year":"2014","journal-title":"Semin Radiat Oncol."},{"issue":"4","key":"2025101514162587400_CIT0003","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","article-title":"Radiation theraspy for brain metastases: An ASTRO clinical practice guideline","volume":"12","author":"Gondi","year":"2022","journal-title":"Pract Radiation Oncol"},{"issue":"1","key":"2025101514162587400_CIT0004","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nat Rev Cancer."},{"issue":"3","key":"2025101514162587400_CIT0005","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1172\/JCI40283","article-title":"Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice","volume":"120","author":"Kioi","year":"2010","journal-title":"J Clin Invest."},{"issue":"6","key":"2025101514162587400_CIT0006","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol Cell."},{"issue":"6922","key":"2025101514162587400_CIT0007","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nature01368","article-title":"DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation","volume":"421","author":"Bakkenist","year":"2003","journal-title":"Nature."},{"issue":"1","key":"2025101514162587400_CIT0008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semradonc.2021.09.008","article-title":"Targeting the ATM Kinase to enhance the efficacy of radiotherapy and outcomes for cancer patients","volume":"32","author":"Garc\u00eda","year":"2022","journal-title":"Semin Radiat Oncol."},{"key":"2025101514162587400_CIT0009","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fphar.2017.00166","article-title":"Targeted nanotechnology in glioblastoma multiforme","volume":"8","author":"Glaser","year":"2017","journal-title":"Front Pharmacol."},{"issue":"1","key":"2025101514162587400_CIT0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer."},{"issue":"2","key":"2025101514162587400_CIT0011","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol"},{"issue":"734","key":"2025101514162587400_CIT0012","doi-asserted-by":"crossref","first-page":"eadj5962","DOI":"10.1126\/scitranslmed.adj5962","article-title":"Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization","volume":"16","author":"Chen","year":"2024","journal-title":"Sci Transl Med."},{"key":"2025101514162587400_CIT0013","article-title":"Substituted 1-(3,3-difluoropiperidin-4-YL)-imidazo[4,5-C] quinonlin-2-one compounds with blood-brain barrier penetrable capability","author":"Zhong","journal-title":"US patent US 11,919,899 G22024"},{"issue":"2","key":"2025101514162587400_CIT0014","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.123.001971","article-title":"Preclinical systemic pharmacokinetics, dose proportionality, and central nervous system distribution of the ATM inhibitor WSD0628, a novel radiosensitizer for the treatment of brain tumors","volume":"390","author":"Rathi","year":"2024","journal-title":"J Pharmacol Exp Ther."},{"key":"2025101514162587400_CIT0015","first-page":"OF1","article-title":"DNA-PK inhibition shows differential radiosensitization in orthotopic GBM PDX models based on DDR pathway deficits","author":"Dragojevic","year":"2024","journal-title":"Mol Cancer Ther."},{"issue":"5","key":"2025101514162587400_CIT0016","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/1535-7163.MCT-23-0552","article-title":"Differential distribution of the DNA-PKcs inhibitor peposertib selectively radiosensitizes patient-derived melanoma brain metastasis xenografts","volume":"23","author":"Ji","year":"2024","journal-title":"Mol Cancer Ther."},{"issue":"9","key":"2025101514162587400_CIT0017","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/genes12091370","article-title":"ATM\u2019s role in the repair of DNA double-strand breaks","volume":"12","author":"Shibata","year":"2021","journal-title":"Genes"},{"issue":"1\u20132","key":"2025101514162587400_CIT0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jns.2015.05.022","article-title":"Ataxia-telangiectasia - A historical review and a proposal for a new designation: ATM syndrome","volume":"355","author":"Teive","year":"2015","journal-title":"J Neurol Sci."},{"issue":"6","key":"2025101514162587400_CIT0019","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpedi.1967.02090270073006","article-title":"Ataxia telangiectasia: Neoplasia, untoward response to X -irradiation, and tuberous sclerosis","volume":"114","author":"Gotoff","year":"1967","journal-title":"Am J Dis Child"},{"issue":"5","key":"2025101514162587400_CIT0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/1097-0142(19820901)50:5<877::AID-CNCR2820500513>3.0.CO;2-U","article-title":"The effects of radiation therapy for Hodgkin\u2019s disease in a child with ataxia telangiectasia: A clinical, biological and pathologic study","volume":"50","author":"Pritchard","year":"1982","journal-title":"Cancer."},{"issue":"17","key":"2025101514162587400_CIT0021","doi-asserted-by":"crossref","first-page":"6687","DOI":"10.1523\/JNEUROSCI.21-17-06687.2001","article-title":"Ataxia telangiectasia mutated-dependent apoptosis after genotoxic stress in the developing nervous system is determined by cellular differentiation status","volume":"21","author":"Lee","year":"2001","journal-title":"J Neurosci."},{"issue":"5366","key":"2025101514162587400_CIT0022","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1126\/science.280.5366.1089","article-title":"Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system","volume":"280","author":"Herzog","year":"1998","journal-title":"Science."},{"issue":"1","key":"2025101514162587400_CIT0023","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1124\/jpet.122.001230","article-title":"Central nervous system distribution of the ataxia-telangiectasia mutated kinase inhibitor AZD1390: Implications for the treatment of brain tumors","volume":"383","author":"Talele","year":"2022","journal-title":"J Pharmacol Exp Ther."},{"issue":"6","key":"2025101514162587400_CIT0024","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-21-0934","article-title":"A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies","volume":"21","author":"Zimmermann","year":"2022","journal-title":"Mol Cancer Ther."},{"issue":"9","key":"2025101514162587400_CIT0025","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","article-title":"The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: The discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)","volume":"61","author":"Pike","year":"2018","journal-title":"J Med Chem."},{"issue":"4","key":"2025101514162587400_CIT0026","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/noaa238","article-title":"Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study","volume":"23","author":"Jucaite","year":"2021","journal-title":"Neuro Oncol"},{"issue":"3","key":"2025101514162587400_CIT0027","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10637-022-01216-8","article-title":"Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors","volume":"40","author":"Waqar","year":"2022","journal-title":"Invest New Drugs."},{"issue":"2","key":"2025101514162587400_CIT0028","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/1535-7163.MCT-24-0664","article-title":"Modeling the acute mucosal toxicity of fractionated radiotherapy combined with the ATM inhibitor WSD0628","volume":"24","author":"Garcia","year":"2024","journal-title":"Mol Cancer Ther."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf102\/62928002\/noaf102.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/9\/2313\/62928002\/noaf102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/9\/2313\/62928002\/noaf102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:16:36Z","timestamp":1760552196000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/27\/9\/2313\/8113364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,4,15]]},"published-print":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf102","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,4,15]]}}}